Isoxazoline is a class of parasiticide drugs used in veterinary medicine to kill fleas, ticks, and mites on dogs and cats. If you’ve come across this term, it’s probably on the label of a popular flea and tick product like Bravecto, NexGard, Simparica, or Credelio. These medications have become some of the most widely prescribed parasite preventives since the first products were approved in 2014, largely because they’re given orally (as a chewable tablet) rather than applied to the skin.
How Isoxazolines Work
Isoxazolines kill parasites by targeting their nervous systems. Specifically, they block a type of nerve channel called a GABA-gated chloride channel. In a healthy insect or tick, these channels help regulate nerve signaling. When an isoxazoline blocks the channel, the parasite’s nerves fire uncontrollably, leading to paralysis and death.
What makes these drugs useful for pets is their selectivity. Isoxazolines bind strongly to the invertebrate version of these nerve channels (found in insects, ticks, and crustaceans) but show no measurable activity on the mammalian version, even at high concentrations. This is why a dose that’s lethal to a flea has minimal direct effect on your dog or cat’s nervous system. The binding site also appears to be different from older insecticides like fipronil, which means isoxazolines can still work on parasites that have developed resistance to previous-generation treatments.
Products in the Isoxazoline Class
Four active ingredients make up the isoxazoline class currently on the market:
- Afoxolaner, sold as NexGard (for dogs)
- Fluralaner, sold as Bravecto (for dogs and cats, in oral and topical forms)
- Sarolaner, sold as Simparica (for dogs) and as part of Revolution Plus (for cats)
- Lotilaner, sold as Credelio (for dogs and cats)
Afoxolaner and fluralaner were the first to receive FDA approval in 2014, followed by sarolaner in 2016 and lotilaner shortly after. All are prescription products in the United States.
What They Protect Against
In the U.S. and Canada, isoxazoline products are approved to treat and prevent flea infestations and to control several tick species: black-legged ticks, American dog ticks, brown dog ticks, and lone star ticks. In Europe, the approved tick coverage extends to the ornate cow tick, castor bean tick, and hedgehog tick. In the EU, Australia, and New Zealand, some isoxazolines are also registered to treat mite infestations, including sarcoptic mange mites and ear mites.
How Quickly They Work
One of the main advantages of isoxazolines is speed. Once your pet takes a dose, the drug is absorbed into the bloodstream. When a flea or tick bites and begins feeding, it ingests the drug. In clinical testing of lotilaner (Credelio), flea kill reached about 90% within 4 hours of the first dose, 99% by 6 hours, and 100% by 12 hours. That speed of kill held up throughout the full dosing period: at every weekly check through day 35, the 12-hour flea kill rate remained at 100%, and the 8-hour rate stayed above 99.5%.
Dosing Intervals
Most isoxazoline products are dosed once a month. The exception is fluralaner (Bravecto), which has a 12-week re-treatment interval per dose. This means full-year flea and tick protection requires about 4.3 doses of Bravecto compared to 12 doses of a monthly product. For pet owners who find it hard to remember monthly treatments, the longer interval can be a practical advantage.
Safety and Side Effects
For most dogs and cats, isoxazolines are well tolerated. The most commonly reported side effects in clinical trials are mild and digestive: vomiting, diarrhea, and temporary loss of appetite. These typically resolve on their own.
The more notable safety concern is neurological. In September 2018, the FDA issued a safety communication alerting pet owners that some animals treated with isoxazoline products had experienced muscle tremors, loss of coordination (ataxia), and seizures. These reactions were identified through post-marketing surveillance, meaning they were reported by pet owners and veterinarians after the drugs were already on the market. The FDA noted that while most dogs and cats have not experienced neurological side effects, seizures have occurred even in animals with no prior history of seizure disorders.
All isoxazoline product labels now carry a warning to use caution in pets with a history of seizures or neurological disorders. If your pet has epilepsy or has had seizures before, this is worth discussing with your veterinarian before starting treatment. The FDA did not pull any of these products from the market, indicating the agency considers the benefits to outweigh the risks for the general pet population, but the alert ensures owners can make an informed choice.
Why Isoxazolines Replaced Older Treatments
Before isoxazolines, the most common flea and tick preventives were topical spot-on treatments applied to the skin between the shoulder blades. These work, but they have practical drawbacks: the application site stays greasy for a day or two, the product can wash off with swimming or bathing, and it can transfer to furniture or to people who pet the animal. Oral isoxazolines eliminated those issues. The drug circulates systemically, so there’s nothing on the coat to rub off or wash away.
The other major shift is efficacy against resistant parasite populations. Because isoxazolines bind to a different site on the nerve channel than older insecticides like fipronil (the active ingredient in Frontline), they remain effective against flea and tick populations that no longer respond well to those earlier products. No cross-resistance with fipronil or dieldrin resistance mutations has been detected in laboratory testing.